Biogen

Eisai reports 3% Q2 FY2024 revenue growth to JPY 385 billion, driven by a 5% increase in its pharmaceutical segment. Despite a slight dip in operating profit to JPY 27.8 billion, flagship products like LEQEMBI show promising growth. LEQEMBI sales reach JPY 16.3 billion globally in H1 FY2024, with significant growth in the U.S. and China. The company maintains full-year revenue and profit forecasts and announces an interim dividend of JPY 80 per share. Eisai focuses on cost control and key product growth, with optimism for future market expansion despite infusion capacity constraints delaying treatment for 6,000 patients.

Climb Bio appoints Douglas E. Williams, Ph.D., as Chair of its Board of Directors, succeeding Andrew Levin, who remains a director. Dr. Williams brings over 30 years of biotech leadership experience, including roles at Sana Biotechnology, Codiak BioSciences, and Biogen.

The neuroscience market, valued at USD 35.3 billion in 2023, is projected to reach USD 50.2 billion by 2032, growing at a CAGR of 4.0%. This expansion is driven by increasing awareness of neurological disorders, advancements in medical technology, and rising healthcare spending. Key technologies like Brain-Computer Interfaces (BCIs), AI, and machine learning are transforming diagnostics and treatments. Notable initiatives such as the BRAIN Initiative and China’s Brain Project are also contributing to market growth.

AbbVie's emraclidine, from the $9 billion Cerevel acquisition, failed in two Phase II trials for schizophrenia, causing a 12% share drop. Despite high placebo response, the drug showed no significant symptom improvement. Analysts are now questioning AbbVie's neuroscience strategy and growth outlook.

The global biotechnology market is projected to reach $550.83 billion in 2024 and $2667.36 billion by 2034, driven by advancements in synthetic biology, CRISPR, and genomic sequencing. North America is expected to lead, with a revenue of $231.68 billion in 2024, due to established agricultural biotechnology and a robust GMO framework. Key players include Johnson & Johnson, Roche, Pfizer, and Novartis.

Innovation in neuropsychiatry is reviving after 40 years of dormancy, with recent approvals like Bristol Myers Squibb’s Cobenfy and Sage Therapeutics’ Zurzuave. Large Phase III studies on psychedelics aim to shift from anecdotal to evidence-based treatments. Challenges include high costs of Phase III trials and lack of effective animal models for CNS disorders. Investment in neuroscience is cyclical, with a need for better patient selection and biomarkers. Infrastructure and less intrusive diagnosis methods, like blood-based biomarkers, are crucial for tackling neurodegenerative diseases. AI and analytics advancements could improve diagnostic efficiency and patient targeting, despite regulatory hurdles and mixed public perception in neuropsychiatry.